ALZpath Demonstrates Global Clinical Impact at AAIC 2026, with Proprietary pTau217 Antibody Anchoring 86 Presentations Demonstrating Clinical and Diagnostic Value Across the Translational Pipeline
Presence builds on 205 original research articles documenting ALZpath’s antibody use across Alzheimer’s blood-based biomarker research CARLSBAD, Calif., July 13, 2026 /PRNewswire/ — ALZpath, Inc., a leading developer of innovative diagnostic tools for Alzheimer’s disease, announced today that data highlighting its proprietary pTau217 antibody will be featured in 86 scientific presentations from 56 leading academic, clinical, and […]
Broad AD/PD™ 2026 Validation Reinforces ALZpath pTau217 Antibody as Industry Benchmark for Blood-Based Alzheimer’s Diagnosis
Data Across 29 Presentations Highlights Precision, Accessibility and Platform-Agnostic Adoption, Establishing ALZpath’s Proprietary pTau217 as a Highly Accurate Industry Benchmark CARLSBAD, Calif., March 17, 2026 /PRNewswire/ — ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer’s disease, today announced the use of its proprietary pTau217 antibody across 29 presentations at the 2026 International Conference […]
ALZpath Commits to Eliminating the ‘D-Word’ to Reduce Stigma and Support Early Alzheimer’s Detection
Company Joins Global Initiative to Replace Outdated Language with Empowering, Patient-Centered Communication Carlsbad, California, February 2nd, 2025 – ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer’s disease, today announced it has signed a formal commitment with the Initiative to Change the “D-Word” to remove the word “dementia” from its communications and materials. This […]
ALZpath-Powered Blood Test Enables Landmark Study on Growing Alzheimer’s Disease Prevalence
First Study to Use a pTau217 Blood Test to Detect Alzheimer’s Disease Early and at Scale CARLSBAD, Calif., December 17, 2025 – ALZpath, Inc., a leading developer of innovative diagnostic tools for Alzheimer’s and related diseases, today announced that the Simoa® ALZpath pTau217 Assay was used in a landmark population-based study published in Nature. The […]
ALZpath and Siemens Healthineers Sign Licensing Agreement to Advance Global Access to Blood-Based Alzheimer’s Disease Diagnostic Testing
Siemens Healthineers will utilize ALZpath’s high-performing, proprietary pTau217 antibody in its growing test menu for its Atellica analyzers to enable IVD testing for Alzheimer’s disease CARLSBAD, Calif., December 15, 2025 – ALZpath, Inc., a leading developer of innovative diagnostic tools for Alzheimer’s disease and related dementias, today announced a licensing agreement with Siemens Healthineers for […]
ALZpath Proprietary pTau217 Antibody Wins BioTech Breakthrough Award for ‘Diagnostics Innovation of the Year’
Transformative Antibody Recognized for Advancing Global Alzheimer’s Disease Detection CARLSBAD, Calif., Nov. 6, 2025 — ALZpath, Inc., a leading developer of innovative diagnostic tools for Alzheimer’s disease, today announced it has been named the winner of the “Diagnostics Innovation of the Year” award by BioTech Breakthrough, a leading independent market intelligence organization that honors excellence in the […]
Global Momentum and Validation Grows at AAIC for ALZpath Proprietary pTau217 Antibody Use in Alzheimer’s Disease Research, Diagnosis, and Treatment
ALZpath pTau217 antibody data included in 37 submissions at AAIC, building on 90 Publications Across 18 Countries demonstrating ALZpath’s superior sensitivity and accuracy in blood-based tests for Alzheimer’s disease CARLSBAD, Calif., July 28, 2025 – ALZpath, Inc., a leading developer of innovative diagnostic tools for Alzheimer’s disease, announced today that data highlighting the ALZpath pTau217 antibody […]
ALZpath Named 2025 BRONZE Edison Award Winner for its Proprietary pTau217 Antibody, a Key Biomarker Driving Blood-Based Alzheimer’s Disease Diagnostics
The ALZpath Antibody is Integral to Advanced Blood Tests for Early Diagnosis of Alzheimer’s Disease and is Widely Available on Research and Clinical Testing Platforms CARLSBAD, California, April 7, 2025 — ALZpath, Inc. (ALZpath), a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced it has been honored with the […]
Data Showcasing ALZpath’s Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer’s Disease Research and Diagnosis
Findings from Studies on Blood Tests Utilizing the ALZpath pTau217 Antibody – Integral to Many Advanced Assays for Research and Clinical Use – Featured in Seven Oral Presentations and Two Posters CARLSBAD, California, April 1, 2025 — ALZpath, Inc. (ALZpath), a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced […]
ALZpath Adds Biotech Veteran to Board of Directors and Names Prominent Global Researcher as Distinguished Scientific Advisor
Samantha Budd Haeberlein, PhD, Joins the Board; Henrik Zetterberg, MD, PhD, Extends Advisory Role, Adding to a Preeminent Group of Multi-Disciplinary Experts Guiding ALZpath’s Innovation Initiatives CARLSBAD, California, March 25, 2025 — ALZpath, Inc., a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced the addition of Samantha Budd Haeberlein, PhD, […]